News That Matters

Tag: treatment

NHS nets 'game-changing' leukaemia treatment

NHS nets 'game-changing' leukaemia treatment

Technology
A cutting-edge personalised treatment for a form of childhood leukaemia is to be made available on the NHS in the first deal of its kind in Europe. NHS England has negotiated a contract with pharmaceutical manufacturer Novartis for a therapy that reprogrammes a patient's immune system to attack cancer cells.The treatment, known as CAR-T (chimeric antigen receptor T-cell) therapy, will be available to children and young people under the age of 25 who have B cell acute lymphoblastic leukaemia.The therapy, which is specifically developed for each patient and is currently only available in Europe in clinical trials, may be available within weeks and could help around 20 children a year.In CAR-T therapy, cells are removed from the patient's blood and reprogrammed into geneticall...
Study: Cetuximab, radiation inferior to standard HPV throat cancer treatment

Study: Cetuximab, radiation inferior to standard HPV throat cancer treatment

Health
Aug. 14 (UPI) -- Treating HPV-positive throat cancer with cetuximab and radiation had worse overall and progression-free survival results compared with the current method of treatment with radiation and cisplatin, the National Institutes of Health revealed Tuesday. The trial, which was funded by the National Cancer Institute, was intended to test whether the combination would be less toxic than cisplatin but be just as effective for human papillomavirus-positive oropharyngeal cancer. The trial, which began in 2011, enrolled 849 patients at least 18 years old with the cancer to receive cetuximab or cisplatin with radiation. The trial is expected to finish in 2020. Cetuximab, which is manufactured under the brand name Erbitux by Eli Lilly, and cisplatin, which as sold as Platinol by Pfizer,...
Research finds potential treatment for obesity, diabetes

Research finds potential treatment for obesity, diabetes

Health
Aug. 9 (UPI) -- Researchers have identified a potential target to treat obesity and diabetes through regulation of energy in the body, according to a study of mice. In findings released Thursday in JCI Insight, researchers from the Colorado School of Medicine outline the biological function of an epigenetic modifier known as histone deacetylase and its potential as a treatment target. White adipose tissue stores energy and brown adipose tissue produces heat, which in turn expends energy. By increasing energy amounts, the researchers believe a regulatory node could lead to new drugs to treat obesity and diabetes. They learned that deleting HDAC11 in mice stimulates brown adipose tissue formation and the absence of the modifier also triggered beiging of white adipose tissue. "Through our i...
Paddy McGuinness receiving treatment after shock medical diagnosis

Paddy McGuinness receiving treatment after shock medical diagnosis

Entertainment
Instagram PADDY MCGUINNESS INSTAGRAM: The Take Me Out presenter revealed his shock arthritis diagnosis The TV star is famed for his happy-go-lucky presenting style on ITV's hit dating show Take Me Out.But the 44-year-old stunned his Paddy McGuinness Instagram followers earlier today when he revealed he has been diagnosed with arthritis.Updating fans from his bed, the dad-of-three posted a picture of himself sporting a grim facial expression.Wearing a pale pink vest top, the Bolton-born talent pointed to a bandage on his shoulder. Christine McGuinness   My goodness my Guinness it's Christine McGuinness. Christine, the wife of comedian and Take Me Out presenter...
FDA approves first non-opioid withdrawal treatment

FDA approves first non-opioid withdrawal treatment

Health
May 17 (UPI) -- The U.S. Food and Drug Administration said it's approved for the first time a non-opioid drug for treatment of opioid withdrawal. The FDA said the drug Lucemyra, made by US WorldMeds, can be used as part of a long-term treatment for managing opioid use disorder. It treats narcotic withdrawal symptoms like vomiting, muscle aches, diarrhea, anxiety, sleep problems and sweats. "We're dedicated to encouraging innovative approaches to help mitigate the physiological challenges presented when patients discontinue opioids," FDA Commissioner Dr. Scott Gottlieb said in a statement. "We know that the physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately overcoming addiction." In 2016, two-thirds of drug overdose deaths in...